August 2011 Archives

Vita Smoked Atlantic Salmon Recalled

August 30, 2011, by JONES WARD PLC

The Consumer Product Safety Commission has announced an urgent recall of 8,088 individual retail packages of 4 oz. Vita Classic Premium Sliced Smoked Atlantic Nova Salmon. The Vita Slamon packaages are being voluntarily recalled due to the potential for contamination with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. However, even healthy individuals may suffer short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea. Importantly, listeria infection can cause miscarriages and stillbirths among pregnant women.

Over 7,260 of the packages were sold at Publix stores in Florida, Georgia, South Carolina, Tennessee, Alabama, Safeway stores in California, Alaska, Oregon, Washington, Idaho, Colorado, Maryland, Virginia, Pennsylvania, and District of Columbia, Meijer stores in Illinois, Michigan, Indiana, Ohio, and Kentucky, Vons stores in California, Genuardi's stores in Pennsylvania and New Jersey, Winn Dixie stores in Florida, and the Edgewater Produce store in Chicago, IL on or after July 25 of this year may be contaminated with Listeria monocytogenes. In addition, 828 individual retail packages of this same product have either possibly been sold or are being offered for sale at various grocery stores in the Buffalo, NY and Pittsburgh, PA metropolitan areas and Northeast Ohio.

If any consumer purchased a product with that SELL BY Date and Code from a retail store on or after July 25, 2011 he or she should not consume any of the Vita Classic Premium Sliced Smoked Atlantic Nova Salmon product. Then, the Company asks that it be sealed in plastic bag or placed in some similar container and returned to the retailer from which it was purchased. The Company is asking that any person who has purchased the product with this SELL BY Date and Code call this telephone number 1-800-989-8482 during the hours of 8am to 5pm (Central Time Zone) Monday through Friday. If you are experiencing any unusual or severe symptoms such as those described above, go to an emergency room immediately or contact your physician for immediate advice.

JONES WARD's product recall attorney provide this message as a public service. We do not handle "food product" injuries unless the consumer has suffered very serious injuries or death as a result of the recalled product.

Toxic Lead Levels Prompt Build-A-Bear Lapel Pin Recall

August 17, 2011, by JONES WARD PLC

Build-A-Bear Workshop and the U.S. Consumer Product Safety Commission recently issued a recall for Build-A-Bear's "Love. Hugs. Peace." lapel pins. According to the Commission, surface paints on these lapel pins contain excessie levels of lead in violation of federal law. The 1.5 inch lapel pin features graphics of a bear head, a heart, and a peace sign positioned in front of a globe. The phrase "Love. Hugs. Peace." appear at the bottom of the pin.

Although no injuries have been reported, lead is a very strong poison that is especially harmful to young children. Children can get lead poisoning from placing lead objects in their mouths or swallowing the object. They can also ingest lead by touching a dusty or pealing lead object and then placing their fingers in their mouths or eating food afterwards. Although it is more common for lead poisoning to build up slowly over time, very high levels of lead may cause seizures, muscle weakness, vomiting, or coma. If someone has severe symptoms from possible lead exposure (i.e. vomiting or seizures) call 911 immediately. For other symptoms call your local poison control center or the National Poison Control Center (1-800-222-1222).

Browning Air Pistol's Recalled Due to Defective Safety

August 17, 2011, by JONES WARD PLC

Umarex USA, a major U.S. importer of air guns, recently issued a recall for the Browning 800 Mag Air pistol. According to the U.S. Consumer Product Safety Commission, a defect with the pistol's safety feature triggered the recall. Under a variety of circumstances, even if engaged, the safety will not prevent the gun from firing. This defect poses a clear risk of serious injury to both users and bystanders. The recalled Browning 800 Mag Air pistols are black and measure 18 inches long. The Browning logo and "800 Mag" are printed on the top of the pistol's barrel block. Consumers can contact Umarex for instructions on how to return the pistol for a free repair. In the interim, users should stop using the pistol immediately and make sure it is unloaded.

Defective Safety Prompts Recall of Browning 800 Mag Air Pistols

August 16, 2011, by JONES WARD PLC

Umarex USA, a major U.S. importer of air guns, recently issued a recall for the Browning 800 Mag Air pistol. According to the U.S. Consumer Product Safety Commission, a defect with the pistol's safety feature triggered the recall. Under a variety of circumstances, even if engaged, the safety will not prevent the gun from firing. This defect poses a clear risk of serious injury to both users and bystanders. The recalled Browning 800 Mag Air pistols are black and measure 18 inches long. The Browning logo and "800 Mag" are printed on the top of the pistol's barrel block. Consumers can contact Umarex for instructions on how to return the pistol for a free repair. In the interim, users should stop using the pistol immediately and make sure it is unloaded.

GM has recalled over 14,000 Chevy Impalas and Buick Lacrosses

August 16, 2011, by Jasper Ward

Chevrolet has recalled over 10,000 Impalas built from April 19, 2011, through July 29, 2011. The recall was placed due to the fact that the upper power-steering hose in some of these models may be routed in such a way that it comes into contact with the car's catalytic converter. The extreme heat from the converter can melt the power-steering hose, which can cause a fire.

Continue reading "GM has recalled over 14,000 Chevy Impalas and Buick Lacrosses" »

Perfect Fitness Agrees to $425,000 Civil Penalty for Failing to Report Product Defect

August 10, 2011, by JONES WARD PLC

Today, the U.S. Consumer Product Safety Commission announced that Perfect Fitness has agreed to a $425,000 civil penalty for failing to report a defect with its fitness product, the Perfect Pullup. The penalty agreement resolves allegations by the Commission that Perfect Fitness knowingly failed to report a defect with the Perfect Pullup that caused the handles of the product to break during use, resulting in a fall hazard to consumers. Federal law requires manufacturers to immediately report to the Commission any information reasonably supporting the conclusion that a product contains a defect which could create a substantial product hazard or an unreasonable risk of serious injury or death.

According to the Commission, Perfect Fitness concluded in June 2008 that its exercise equipment was defective following re-testing of the handle design. In July 2008, Perfect Fitness redesigned the product to correct the defect. Commission staff alleges that Perfect Fitness was aware of at least 23 injuries associated with its product in March 2010 when it posted a notice on its website to inform consumers how to receive free replacement handles. Perfect Fitness did not report any defect to the Commission until December 2010. At that time, the Commission alleges that Perfect Fitness had received more than 2,000 requests for replacements and was aware of at least 45 complaints of injury associated with defective handles.

In February 2011, Perfect Fitness and the Commission announced a recall of approximately 7,000 Perfect Pullups. The exercise equipment sold for between $80 and $100 from January 2008 through February 2011.

Honda Recalls Over 1.5 Million Vehicles

August 9, 2011, by JONES WARD PLC

Honda has made a decision to recall 1.5 million-plus vehicles in the United States for purposes of updating a software program that runs its transmissions. The software update is being done for purposes of decreasing the possibility of transmission damage. However, if the software fix is not implemented, it could lead to safety issues. Therefore, please call your Honda dealer and get this problem fixed as soon as possible. Believe me, recalls are not cheap. Honda would not be doing this unless there was serious risk to you and your car. The recall affects certain 2005-2010 4-cylinder Accord, 2007-2010 CR-V and 2005-2008 Element vehicles.

Jones Ward PLC's lawyers have experience with representing people that have been injured by cars that have been recalled or should have been recalled because of various defects. Therefore, we know that you should take this recall notice seriously.

FDA: Actos Bladder Cancer Risk

August 9, 2011, by JONES WARD PLC

The federal Food & Drug Administration has approved updated label information for pioglitazone (Actos), following its warning in June about bladder cancer risk with the drug.

The updated label recommends against use of Actos in patients with active bladder cancer and urges cautious use by physicians in those with a history of bladder cancer.

Screen shot 2011-08-09 at 7.54.48 AM.png

The new labeling, released by the FDA this past Friday, warns that use of Actos for more than a year may increase the risk of bladder cancer. The findings are based upon scientific studies.

It also urges patients to contact their healthcare provider if they experience any potential symptoms of bladder cancer, including blood in their urine, urinary urgency, or pain on urination.

The original warning on pioglitazone was based on an interim review of an ongoing epidemiological study of almost 200,000 diabetic patients by drugmaker Takeda, and came just days after France and Germany banned use of the drug. The analysis found a 1.4-fold increased risk of bladder cancer with two years of treatment, although the agency said the finding was of "nominal" significance.

Jones Ward PLC's pharmaceutical injury team is actively evaluating the Actos bladder cancer risk cases. It is simply unconscionable that Takeda continues to sell this drug in the United States after France and Germany banned the drug. It is time to pull this highly profitable drug from the market.


Actos: Bladder Cancer

August 9, 2011, by JONES WARD PLC

Takeda Pharmaceuticals Co. Ltd., which manufactures of the best selling diabetes drugs in the world, is facing several hundreds of lawsuits due to recent reports that patients who take the bill for a year or longer may develop bladder cancer.

actos-pioglitazone-hydrochloride.jpg

Actos was pulled from the market in Germany and France in June "after pressure from regulators" in the two countries, which raises the question of why the US has not halted sales of this highly profitable drug. FDA and the European Medicines Agency have "issued warnings about the cancer risk based on new research, but they have allowed sales to continue."

Jones Ward PLC's lawyers are experienced pharmaceutical injury lawyers. We are currently evaluating Actos bladder cancer cases. If you would like to have your case evaluated free of charge, feel free to contact us.

Anti-Depressants Cause Birth Defects, Studies Show

August 8, 2011, by Jasper Ward

There has been more information and studies these last few years showing the serious side effects that anti-depressants taken during pregnancy can have on babies. Prozac, Paxil, Welbutrin, Lexapro and Zoloft are common brand names of drugs known as SSRIs - selective serotonin reuptake inhibitors. These drugs regulate the amount of serotonin, the chemical in the brain most closely associated with depression.

Unfortunately, these brain chemicals are also critical during the development of the fetus, meaning that drugs affecting the balance and amount of serotonin in the brain during certain times of pregnancy can cause birth defects, specifically related to the heart. Aortic stenosis, a hole in the heart or cleft palates, among other birth defects.

The use and safety of anti-depressants during pregnancy is still controversial and many doctors will tell patients - following the drug companies warnings - that it can be safe during most of the pregnancy. However, because there cannot be widespread trials on women who are pregnant, only animals, it is difficult to produce enough reliable data. Anti-anxiety medicine, such as Topamax, has also been shown to cause birth defects in newborn babies. Until the link is established or a more complete look at the data by the drug companies is performed, any woman who is pregnant and taking these sorts of medications should talk to their doctor and ask questions about the safety of these drugs.

Continue reading "Anti-Depressants Cause Birth Defects, Studies Show" »

Target Step Stools Recalled

August 7, 2011, by JONES WARD PLC

JONES WARD PLC has learned that the United States Consumer Product Safety Commission ("CPSC") has announced a recall of over 206,000 step stools sold at Target stores nationwide. The CPSC recall notice advised consumers that the step stools may break under the weight of the user, which poses a serious fall and serious injury risk. To date, Target has notified the CPSC of 26 reports of stools breaking, including nine injuries. However, as JONES WARD's lawyers know from experience, the CPSC receives reports of very few of the actual injuries that occur because most consumers are not aware of the reportiing process.

Zimmer Durom Hip Implant Failures

August 5, 2011, by JONES WARD PLC

On July 24, 2008, nearly three years ago, Zimmer Holdings, the nation's largest producer of orthopedic devices, announced that it was suspending the sales of an artificial hip implant component due to its high failure rate. The medical device, a hip socket known as the Durom cup, was first sold in the U.S. in 2006 and has been implanted in 12,000 patients.

If you had hip surgery in 2006 through July 2008, and your implant is failing or must be replaced, you should contact your physician's office. Ask to be sent the page in your medical records which lists the manufacturer of your artificial hip and see if you received the Zimmer Durom Cup.

If you have the Zimmer Durom Cup, then you have a legal claim against Zimmer for the damages caused by the implant. Jones Ward PLC's attorneys have negotiated settlements for our clients that cover not only their medical bills but also provide for recovery related to the pain and suffering caused by the implant. In some cases, if the settlements are not acceptable, Jones Ward's experienced product liability team will file a lawsuit.

Zimmer Durom

For more information, feel free to call us or send an email anytime. We normally respond within an hour of receipt.

Kroger Turkey Recall

August 5, 2011, by JONES WARD PLC

My partner, Jasper Ward, wrote about the turkey recall earlier this week. You can read it here. Interestingly, we just received a recorded call at my house from Kroger, a regional grocery store where we shop. Kroger announced the recall and warned their shoppers about the danger of the turkey. As my wife said, "They never would have done that without pressure from lawyers like you." She's right. I don't intend to sue anyone about bad turkey, but I'm glad that what I do makes a small difference in this world. Whenever I get tired of working, I think about the fact that products are much safer today than they were 20 years ago. And its all because of lawyers holding companies accountable for their actions.

MDL Primer: Multi-District Litigation 101

August 5, 2011, by JONES WARD PLC

This is an article that is scheduled to be published in the upcoming issue of the Kentucky Justice Association's Advocate Magazine.

By: Lawrence L. Jones II

Almost all attorneys have at least a vague understanding of what a "mass tort" is but few know about the Multi-District Litigation (or "MDL") device that was created by Congress in 1968 to efficiently manage mass tort litigation in federal courts. Many Plaintiffs' lawyers try to avoid the MDL process like the plague. These lawyers believe that an MDL ultimately delays the resolution of their clients' cases because of the lengthy "life cycle" of an MDL. Some also resent paying a "case tax" (sometimes as high as 10%) to the members of the MDL's steering committee, a panel of lawyers appointed by the transferee court to litigate the issues common to all of the cases.

Regardless of what your thoughts are about the MDL process, it pays to know what an MDL is before your case suddenly becomes part of one against your will. The following is a primer based upon the author's experiences handling numerous MDL cases, both as class counsel and as appointed members on the Plaintiff's Steering Committee and various subcommittees.

What is the Judicial Panel on Multi-District Litigation?

Congress created the United States Judicial Panel on Multi-District Litigation with its passage of 28 U.S.C. §1407. The MDL Panel consists of seven United States District and Circuit Court Judges (each serving a seven-year term), including its Chairman. Unbeknownst to many Kentucky attorneys, United States District Court Judge John G. Heyburn II currently serves in the prestigious role of Chairman of the MDL Panel. The Chief Justice of the United States Supreme Court selects both the Chair and the MDL panelists.

The MDL Panel was created by Congress to determine whether civil cases filed in various federal jurisdictions share common questions of fact that may make them appropriate for centralization in one federal district court for coordinated pre-trial proceedings. This centralization process is intended to avoid duplicative discovery, to prevent inconsistent pretrial rulings in factually similar cases and to conserve the resources of the parties who may be managing hundreds or even thousands of similar cases across the United States.

Since its creation, the MDL Panel has considered centralization motions involving more than 300,000 cases, involving millions of claims. While many think of the MDL process as something that applies to pharmaceutical cases, the MDL Panel's docket is much more diverse. In addition to pharmaceutical cases, the MDL Panel has considered cases involving wage and hour litigation, airplane crashes, train wrecks, hotel fires, asbestos, securities and financial fraud, antitrust, and patent cases. However, it is true that the bulk of the MDL Panel's docket does include pharmaceutical cases.


How does a case get selected for MDL treatment?

A case does not just automatically get selected for MDL treatment; one of the parties must ask for such treatment. To begin the process of creating an MDL, a party must file a motion pursuant to 28 U.S.C. §1407 requesting centralization of all similar cases for purposes of conducting pre-trial proceedings. The motion is filed with the MDL Panel and a copy of such motion must be filed with district court in which action is pending. Koerner & Associates, Inc. v. Aspen Labs, Inc., 492 F.Supp 294 (S.D. Tex. 1980).

The party seeking centralization must make a showing that the pending cases are factually similar and that centralization will benefit the parties and conserve judicial resources. The moving party bears a strong burden of showing that common questions of fact are so complex and that the accompanying discovery is so time consuming as to overcome the inconvenience to the party whose action is being transferred. In re Interstate Medicaid Patients at Good Samaritan Nursing Center, 415 F.Supp 389 (JPML 1976).

Is there anything I need to know about practicing before the MDL Panel?

If one intends to practice before the MDL Panel, you are advised to carefully review the Rules of Procedure of the Judicial Panel on Multi-District Litigation. The Rules are a guide to the MDL Panel's mandates for such things as service of process, number of copies, style of pleadings, and relevant deadlines.

For illustrative purposes, the following scenario assumes that it is the plaintiff who has filed a 1407 motion for centralization, although defendants also file such motions because of the economic advantages of litigating and/or settling hundreds or thousands of cases in a centralized manner.

After a plaintiff files a 1407 motion seeking centralization, the MDL clerk will notify all of the parties of the motion's filing date, caption, MDL docket number, briefing schedule and the pertinent MDL Panel policies. JPML Rule 7.2(b). The defendants must respond within 20 days (or seek an extension of time pursuant to JPML Rule 6.2) or the Defendant is deemed to have acquiesced to the request for MDL centralization. JPML Rule 7.2(c).

The initial motion for centralization must include averments in numbered paragraphs, each of which shall be limited, as far as practicable, to a statement of a single factual averment. The response to those averments in motions shall be made in numbered paragraphs, each of which shall correspond to the number of the paragraph of the motion to which the responsive paragraph is directed. Much like an answer to a complaint, each responsive paragraph must admit or deny wholly or in part the averment of the motion, and shall contain the respondent's version of the subject matter when the averment or the motion is not wholly admitted. JPML Rule 7.2.

Within eleven days after the motion for MDL transfer is filed, each party or designated attorney must enter an appearance by notifying the MDL Panel's Clerk, in writing, of the name and address of the attorney designated to receive service of all pleadings, notices, orders and other papers relating to practice before the MDL Panel. JPML Rule 5.2(c). Only one attorney shall be designated for each party.

The response to the 1407 motion, which is due within 20 days, must also include a brief in support thereof in which the background of the litigation and factual and legal contentions of the respondent shall be concisely stated in separate portions of the brief with citation to applicable authorities. JPML Rule 7.2(a)(i). All briefs are limited to twenty pages, exclusive of exhibits, unless the MDL Panel orders otherwise. JPML 7.2(f).

In addition to the response brief, each responding party is required to simultaneously file a one page statement indicating the responding party's position regarding whether oral argument before the MDL Panel is necessary or not, including the reasons why. JPML Rule 16.1(b).

If there is an objection to the 1407 motion for centralization, the MDL Panel will not transfer the case without a hearing on the motion except in cases where the MDL Panel determines that: (i) the dispositive issues have been authoritatively decided; or (ii) the facts and legal arguments are adequately presented in the briefs and record, and oral argument would not be helpful to the MDL Panel's decision-making process. JPML Rule 16.1(c).

All parties and counsel are also required to promptly notify the MDL Panel's Clerk of any potential "tag-along actions" in which that party is also named or in which that counsel appears. JPML Rule 7.2(i). A "tag-along action" refers to a case that is pending in a federal district court and involving common questions of fact with actions previously transferred under Section 1407. JPML Rule 1.1.

Once the MDL Panel schedules the oral argument which normally takes place at the MDL Panel's next bi-monthly hearing, you will appear at the hearing to present reasons why the cases should be centralized and to argue to the MDL Panel which jurisdiction would be appropriate for centralization.

Once at the MDL Panel's hearing, it is very important that counsel limit oral argument to the "appropriate criteria" as spelled out in In re East of the Rockies Concrete Pipe Antitrust Cases, 302 F. Supp. 244, 255-56 (J.P.M.L. 1969). In sum, there are twenty questions that the East of the Rockies case focuses on.

Among other things, the MDL Panel wants to know a) How many common questions of fact are there and what is the nature of the common questions?; b) How many cases have been filed, where they are currently venued, whether additional cases will be filed and the anticipated venues of those filings; c) Whether transfer and centralization will operate to save the parties and the courts from duplicative work and inconsistent rulings; d) What detriment, financial or otherwise, will be imposed upon any of the parties by ordering transfer?; e) Are pretrial proceedings already far along in any one or more of the cases?; f) What is the availability of a judge in the proposed transferee court or courts?; g) Will the advantages of transfer and centralization overcome the normal desirability of having the same judge who conducts the trial also conduct pretrial proceedings?; and h) Will transfer and centralization impede or promote the prospect of settlements?

The hearing itself is a very interesting experience. Hundreds of plaintiff and defense lawyers come from across the country to attend the MDL hearing. Yet, most of the lawyers are merely observers since the MDL Panel limits the oral argument time. If the plaintiffs and the defendants agree that the cases should be centralized, then the arguments many times focus on which court would be the appropriate transferee court. Factors argued by the parties, and considered by the Court, are: a) Whether the proposed venue has a major airport nearby which would accommodate counsel traveling from across the country; 2) The location of the corporate defendants; 3) The proximity of evidence and witnesses to the proposed venue; and 4) The desire of the proposed transferee judge to handle a complex and time-consuming MDL proceeding.

What Happens After the MDL Hearing?

The MDL Panel is generally pretty quick with its decisions. The MDL Panel usually issues a ruling on 1407 motions within two weeks after the hearing. The order will mandate whether or not the cases are to be centralized and, if so, to which federal district court judge the cases are transferred. So, generally, the process takes approximately 90 days from the filing of the motion until the MDL Panel's ruling is issued -which has been a marked improvement under Judge Heyburn's leadership.

Once the MDL Panel chooses the transferee court, the transferee judge assumes control over all current and future cases involving the common questions and common defendants. In re Equity Funding Corp. of America Securities Litigation, 375 F.Supp 1378 (JPML 1973) (It is province of Judicial Panel to decide in the first instance whether litigation should be transferred for coordinated or consolidated pretrial proceeding while it is the province of transferee judge to determine whether and to what extent the trial proceedings should be coordinated or consolidated.) Indeed, the transferee court assumes complete jurisdiction for pre-trial purposes and has authority to settle all pre-trial motions including dispositive motions such as those for summary judgment or approval of a settlement. In re Agent Orange Product Liability Litigation, 597 F.Supp 740 (E.D.N.Y. 1984), affirmed, 818 F.2d 145, cert. denied, 108 S.Ct. 695, 484 U.S. 1004, 98 L.Ed.2d 648, on remand, 689 F.Supp. 1250. The transferee court is also authorized to handle matters relating to class action certification in order to prevent inconsistent rulings and to promote judicial efficiency.

After the MDL Panel issues its ruling and transfers the cases for coordinated proceedings, the transferee judge promptly schedules a conference with all lawyers involved in the litigation. At this initial status conference, the transferee court will begin to address case management issues (such as electronic preservation of evidence, the use of master complaints, service of process issues, etc.) that will be included in the Case Management Order (or "CMO"). Additionally, the Court usually appoints temporary lead or liaison counsel to be the spokespersons for the Plaintiffs and the Defendants, until such time as permanent lead or liaison counsel can be appointed.

Since there may be hundreds or even thousands of plaintiff lawyers involved in a particular MDL, the transferee court cannot possibly accommodate having that many lawyers appear at hearings and expect to be heard. Therefore, the transferee court
will issue an order relating to applications for a position on the Plaintiff's Steering Committee ("PSC"). Alternatively, the Court may ask the temporary lead counsel to propose a "slate" for potential appointment on the PSC. Sometimes the applications, which are largely recitations of one's experience with complex cases, can be quite colorful. In the recent round of applications for the Toyota MDL, one lawyer touted that he had donated an organ to a family member as an example of his selfless nature.

After the PSC is appointed by the court, the lawyers on the PSC will control the litigation for all of the non-PSC members. All case strategy and much of the day-to-day work is completed by the PSC and the various "sub-committees" created by the PSC. Yet, once the discovery is complete regarding the issues common to all of the cases, the PSC's work is done and the individual cases are remanded to their home district for trial.

What happens after the discovery is finished?

After several years of being constantly bombarded with electronic filings from the MDL case, one day you may realize that the parties have finally completed discovery. By this time, Daubert motions related to general causation experts have been resolved, expert depositions have been completed, and the corporate officers have been deposed. What happens next?

Well, the individual plaintiff lawyer finally regains control of his/her own individual case. As a benefit of the "tax" that you will be required to pay to the PSC upon settlement of your case, you will receive access to the millions of documents that have been unearthed during discovery. In fact, you will have access to all of the discovery completed in the case, including the expert depositions. From there, you are on your own to try your case (or engage experienced co-counsel chosen from the PSC) and hold the individual corporate wrongdoer accountable for its conduct.

Right or wrong, like it or not, this is how a case proceeds through the MDL process! If you don't like it, find a non-diverse defendant to sue and fight like mad to keep the action in state court.

Lawrence L. Jones II is a founding partner of Jones Ward PLC in Louisville, Kentucky. His firm focuses much of its practice on mass tort litigation in state and federal courts across the country. The firm is currently involved in several MDL proceedings. For more information about the author, visit www.the-recall-lawyers.com.

Build-A-Bear Recalls Lapel Pins Due to Lead Paint

August 4, 2011, by JONES WARD PLC

For all of you guys out there like me with small children with lots of Build-A-Bear loot in the house, check out this recall from the Consumer Product Safety Commission. I certainly don't intend to bring any lawsuits over this, but I do want my friends to know about the dangerous products that are in our homes. If you have Build-A-Bear toys in your house, please make sure that you don't have this lapel pin.

build-a-bear-logo-blessings-abound-mommy.gif

Build-A-Bear Workshop Recalls Lapel Pins Due to Violation of Lead Paint Standard

WASHINGTON, D.C. - The U.S. Consumer Product Safety Commission and Health Canada, in cooperation with the firm named below, today announced a voluntary recall of the following consumer product. Consumers should stop using recalled products immediately unless otherwise instructed. It is illegal to resell or attempt to resell a recalled consumer product.

Name of Product: Love.Hugs.Peace lapel pins

Units: About 26,500 pins in the United States and 2,200 in Canada

Importer: Build-A-Bear Workshop(r), of St. Louis, Mo.

Hazard: Surface paints on the lapel pin contain excessive levels of lead which is prohibited under federal law.

Incidents/Injuries: No injuries have been reported.

Description: The 1.5 inch lapel pin features graphics of a heart, bear head, and peace sign all positioned in front of a globe. The words "Love.Hugs.Peace." appear at the bottom of the pin.

Sold by: Build-A-Bear Workshop stores nationwide and online at www.buildabear.com from July 2009 through October 2010 for $3.50 in the US and $4 (CDN) in Canada.

Manufactured in: China

Remedy: Stop using the lapel pins and return the lapel pin to any Build-A-Bear Workshop store to receive a $5 store coupon. If it is not possible to return the pin to a store, you can contact the company for alternate instructions on receiving a refund.

Consumer Contact: For additional information, please contact Build-A-Bear Workshop toll-free at (866) 236-5683 between 8 a.m. and 6 p.m. CT Monday through Friday, between 9 a.m. and 4 p.m. CT Saturday, or visit the company's website at www.buildabear.com

To see this recall on CPSC's web site, including a picture of the recalled product, please go to:
http://www.cpsc.gov/cpscpub/prerel/prhtml11/11298.html

Salmonella Turkey From Cargill Recalled By Government

August 3, 2011, by Jasper Ward

Following up on our post from earlier this week, the company behind the tainted turkey has finally been named: Cargill. The company issued a "voluntary" recall of its ground turkey products from dozens of states after nearly one hundred reported injuries and one death from an especially dangerous form of salmonella.

Cargill-articleInline.jpg

The Cargill subsidiary, Cargill Value Added Meats Retail, sold the product under the brand Honeysuckle White and included turkey produced at the plant that is the source of the problem since February. Cargill is shutting down the plant until they determine what is wrong that is causing the poisoning.

Salmonella exposure can cause numerous health problems, including fever and blood poisoning. The meat was sold at Kroger, which has a large presence in Kentucky.

Cargill has recalled more than 36 million pounds of turkey.

Continue reading "Salmonella Turkey From Cargill Recalled By Government" »

Medtronic Paid Surgeons Who Miminized Risk of Bone Growth Product

August 1, 2011, by Jasper Ward

Medtronic, the national device manufacturer that is a defendant in numerous lawsuits over pain pump and other recalled or dangerous devices, is the subject of a new controversy. According to the Spine Journal, the nationally recognized leading journal for medical research and articles dealing with the spine and back, Medtronic promoted the Infuse bone growth product for use in spinal fusion surgeries. According to the New York Times, the Spine articles highlighted how surgeons with financial backing from Medtronic vastly downplayed the serious risks of injury to patients and overstated the product's benefits.

In fact, the Medtronic-paid doctors claimed there were no risks. In a highly unusual, inter-medicine editorial, the writers at Spine Journal called out their colleagues: "It harms patients to have biased and corrupted research published" and went on to say that it harmed patients to have "unaccountable special interests permeate medical research."

The side effects from the Infuse include infection, bone loss, male sterility, and unwanted bone growth. The FDA recently rejected a stronger Medtronic product similar to the Infuse because of a link to increased risk of cancer.

In our cases, we've seen drug companies highlight journal articles and studies that supposedly show the risk of their drugs or devices are minimal. However, drug companies often pay for these studies, and we have seen certain manufacturers exclude data as "outliers" - when that data shows clearly the increased risk of their product.

Continue reading "Medtronic Paid Surgeons Who Miminized Risk of Bone Growth Product" »